MDGL

300.16

0.82% -2.48

Dopo l'orario di chiusura: 300.16

Madrigal Pharmaceuticals Inc (MDGL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MDGL Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$302.64

Aprire:

$300.01

Volume 24 ore:

217.85K

Relative Volume:

0.69

Capitalizzazione di mercato:

$6.27B

Reddito:

Utile/perdita netta:

$-518.67M

Rapporto P/E:

-11.95

EPS:

-25.12

Flusso di cassa netto:

$-438.32M

1 W Prestazione:

+5.33%

1M Prestazione:

+9.05%

6M Prestazione:

-2.73%

1 anno Prestazione:

+7.46%

Intervallo 1D:

$291.45

$301.39

Intervallo di 1 settimana:

$277.64

$314.22

Portata 52W:

$200.63

$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Nome

Madrigal Pharmaceuticals Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

404-380-9263

Indirizzo

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Dipendente

528

Cinguettio

@MadrigalPharma

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

MDGL's Discussions on Twitter

Confronta MDGL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MDGL Madrigal Pharmaceuticals Inc	300.16	6.27B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	452.16	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	534.91	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.06	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.47	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.16	28.51B	3.81B	-644.79M	-669.77M	-6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-28	Aggiornamento	B. Riley Securities	Neutral → Buy
2025-02-27	Reiterato	H.C. Wainwright	Buy
2024-06-28	Iniziato	Cantor Fitzgerald	Neutral
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-04-22	Iniziato	BofA Securities	Underperform
2024-03-15	Aggiornamento	B. Riley Securities	Sell → Neutral
2024-03-06	Iniziato	Citigroup	Buy
2024-02-26	Downgrade	B. Riley Securities	Neutral → Sell
2022-12-20	Reiterato	Oppenheimer	Outperform
2022-12-19	Reiterato	H.C. Wainwright	Buy
2022-12-19	Reiterato	Piper Sandler	Overweight
2022-12-19	Aggiornamento	Raymond James	Underperform → Mkt Perform
2022-07-08	Downgrade	B. Riley Securities	Buy → Neutral
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Ripresa	Goldman	Buy
2020-11-24	Ripresa	Evercore ISI	Outperform
2020-11-06	Reiterato	H.C. Wainwright	Buy
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-06-05	Iniziato	BMO Capital Markets	Market Perform
2020-05-05	Iniziato	Chardan Capital Markets	Buy
2020-01-30	Iniziato	Canaccord Genuity	Buy
2020-01-09	Aggiornamento	UBS	Neutral → Buy
2019-11-07	Reiterato	H.C. Wainwright	Buy
2019-06-25	Iniziato	Stifel	Hold
2019-06-10	Aggiornamento	B. Riley FBR	Neutral → Buy
2019-02-28	Reiterato	H.C. Wainwright	Buy
2019-02-22	Iniziato	SVB Leerink	Outperform
2019-01-23	Iniziato	UBS	Neutral
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-12-12	Iniziato	B. Riley FBR	Neutral
2018-11-19	Downgrade	Raymond James	Mkt Perform → Underperform
2018-11-16	Aggiornamento	Evercore ISI	In-line → Outperform
2018-09-04	Iniziato	Citigroup	Buy
2018-08-06	Downgrade	Goldman	Buy → Neutral
2018-06-28	Iniziato	Raymond James	Mkt Perform

Mostra tutto

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus

Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 17, 2025

Jun 16, 2025

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com

Jun 16, 2025

Jun 15, 2025

(MDGL) Investment Analysis - news.stocktradersdaily.com

Jun 15, 2025

Jun 13, 2025

Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN

Jun 13, 2025

Jun 11, 2025

Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025

Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World

Jun 11, 2025

Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025

Jun 09, 2025

Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 09, 2025

Jun 06, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 06, 2025

Jun 03, 2025

(MDGL) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025

Jun 02, 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire

Jun 02, 2025

May 29, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World

May 29, 2025

May 28, 2025

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com

May 28, 2025

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025

May 25, 2025

Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

May 25, 2025

May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025

May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025

May 16, 2025

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com

May 16, 2025

May 15, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025

May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025

May 08, 2025